Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (8)

2023

  1. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  2. Risk factors for anastomotic leakage and postoperative outcomes after total and subtotal colectomy: A nationwide retrospective cohort study (RIALTCOT Study Collaborative Group)

    Colorectal Disease, Vol. 25, Núm. 3, pp. 420-430

2022

  1. A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer

    Gastroenterology, Vol. 163, Núm. 5, pp. 1242-1251.e2

  2. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  2. Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

    Molecular Diagnosis and Therapy, Vol. 25, Núm. 5, pp. 563-576

2015

  1. Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273

  2. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastricneuroendocrine tumour

    Human Molecular Genetics, Vol. 24, Núm. 10, pp. 2914-2922